Riskpilot← Back to searchSign inGet full accessTermino C 10712 AB
ABDissolvedOrg 5568585706Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20117 employees
Revenue 2022
SEK 5,9M
-73% vs 2021
EBITDA margin
-19.5%
-122% vs 2021
Equity ratio
47.8%
Financial strength
Net profit 2022
SEK 224K
-93% vs 2021
| Revenue | SEK 5,9M | -73% |
| EBITDA | SEK -1,1M | -122% |
| Net profit | SEK 224K | -93% |
| Total assets | SEK 3,5M | -56% |
| Equity | SEK 1,7M | -45% |
| Employees | 7 | — |
Legal name
Termino C 10712 AB
Org number
5568585706
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4 juli 2011
Share capital
SEK 50 000
Employees
7 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget skall bedriva förvaltning av värdepapper samt därmed jämförlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 7 018 | 6 188 | 14 140 | 21 987 | 5 875 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 469 | −117 | 1 077 | 5 134 | −1 144 |
| Depreciation & amort. | −8 | −8 | −15 | −60 | −115 |
| EBIT | 461 | −125 | 1 062 | 5 074 | −1 259 |
| Net financials | −302 | 89 | −61 | −5 | 1 |
| Profit before tax | 102 | 22 | 725 | 3 790 | 298 |
| Tax | −39 | −18 | −178 | −794 | −74 |
| Net profit | 63 | 4 | 547 | 2 996 | 224 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 3 185 | 2 914 | 3 315 | 8 041 | 3 512 |
| Equity | 483 | 488 | 1 035 | 3 051 | 1 679 |
| Long-term debt | 618 | 466 | 0 | 0 | 0 |
| Short-term debt | 2 026 | 1 961 | 2 005 | 3 434 | 1 833 |
| Total debt | 2 644 | 2 427 | 2 005 | 3 434 | 1 833 |
EBITDA margin
-19.5%
This company
15.8%
Market median
-223% vs market
20182022
Equity ratio
47.8%
This company
38.2%
Market median
+25% vs market
20182022
Return on equity
13.3%
This company
18.4%
Market median
+28% vs market
20182022
Net profit margin
3.8%
This company
8.1%
Market median
-53% vs market
20182022
Asset turnover
1.67×
This company
1.12×
Market median
+49% vs market
20182022
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
HM | Audit | 2020 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Former (3) | ||
| Chairman | 2021 – 2022 | |
| Deputy Board Member | 2020 – 2024 | |
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Termino C 10712 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helén Marita Lyckstedt | Audit | 0 companies |
| Franco Salluzzi | Chairman | 0 companies |
| Katarina Helga Teresia Salluzzi | Deputy Board Member | 0 companies |
| Anders Jakob Lindquist | Deputy Board Member | 0 companies |
| Nils Thomas Carlsson | Board of Directors | 0 companies |
| Torbjörn Nordberg | Board of Directors | 0 companies |